Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05484973 · ClinicalTrials.gov registry record · NA
Study to Assess the Ability of the Portable Scalp Cooling System (PSCS) to Prevent Hair Loss
A NA study of Breast Cancer and Alopecia, sponsored by Cooler Heads Care.
- Recruiting
- Registry status
- NA
- Development phase
- 99
- Enrollment target
- 2
- Study locations
NCT05484973: Recruiting NA study of Breast Cancer and Alopecia, sponsored by Cooler Heads Care.
NCT05484973 is a NA study of Breast Cancer and Alopecia that is actively recruiting participants, run by Cooler Heads Care. The registered enrollment target is 99 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05484973, a NA study of Breast Cancer and Alopecia, is actively recruiting participants, sponsored by Cooler Heads Care.
- RECRUITING
- Registry status
- NA
- Development phase
- 99 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this prospective study is to assess the ability of AMMA to prevent hair loss in women receiving chemotherapy (CT) for early-stage breast cancer. Additionally, the purpose is also to assess the safety, tolerability and compliance, quality of life, and satisfaction with hair preservation after CT treatment.
Primary Outcome
To evaluate hair loss as assessed by the investigator at 3 weeks (±1 week) after the completion of the last CT treatment/infusion visit using the Common Terminology Criteria for Adverse Events (CTCAE) post-treatment, by photographs, compared to baseline photographs.
Conditions Studied
Interventions
- DEVICE AMMA Portalbe Scalp Cooling System
Study Locations (2)
Arizona
- University of Arizona - Tucson
Illinois
- Carle Health - Urbana
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2024-11-08 |
| Est. Completion | 2026-09-30 |
| Phase | NA |
What NCT05484973 shows while recruiting
NCT05484973 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 99 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower).
The record links to 4 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which AMMA Portalbe Scalp Cooling System is the first listed.
NCT05484973 reports a single indexed study location in Arizona, Illinois.
Frequently Asked Questions
What is clinical trial NCT05484973 about?
NCT05484973 is a clinical study titled "Study to Assess the Ability of the Portable Scalp Cooling System (PSCS) to Prevent Hair Loss". The purpose of this prospective study is to assess the ability of AMMA to prevent hair loss in women receiving chemotherapy (CT) for early-stage breast cancer. Additionally, the purpose is also to assess the safety, tolerability and compliance, quality of life, and satisfaction with hair preservatio...
What is the current status of trial NCT05484973?
This trial is currently recruiting. It is a NA study. The enrollment target is 99 participants. The study started on 2024-11-08. Estimated completion is 2026-09-30.
What conditions does trial NCT05484973 study?
This clinical trial studies the following conditions: Breast Cancer, Alopecia, Hair Loss, Chemotherapy-induced Alopecia.
What interventions are being tested in trial NCT05484973?
The interventions under investigation include: AMMA Portalbe Scalp Cooling System (DEVICE).
Who is sponsoring clinical trial NCT05484973?
This trial is sponsored by Cooler Heads Care, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05484973 being conducted?
This trial has 2 study locations across Arizona, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05484973's enrollment target sits among peer trials
99 596th of 1224 higher than 628 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
-
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
RECRUITING · NA
-
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
RECRUITING · NA
-
A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03965234 · 99 participants · Phase 1
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
- NCT04042844 · 99 participants · Phase 2
A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
- NCT04143724 · 99 participants · Phase 2
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
- NCT04302025 · 99 participants · Phase 2
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI